| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MFAP5 |
| Uniprot No | Q13361 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-173aa |
| 氨基酸序列 | IPLGVNSQRGDDVTQATPETFTEDPNLVNDPATDETVLAVLADIAPSTDDLASLSEKNTTAECWDEKFTCTRLYSVHRPVKQCIHQLCFTSLRRMYIVNKEICSRLVCKEHEAMKDELCRQMAGLPPRRLRRSNYFRLPPCENVDLQRPNGL |
| 预测分子量 | 33.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MFAP5重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "MFAP5 promotes tumor progression and bone metastasis by regulating ITGAV in prostate cancer"
**作者**: Chen Y, et al.
**摘要**: 该研究通过重组MFAP5蛋白体外实验，揭示了MFAP5通过调控整合素ITGAV信号通路促进前列腺癌骨转移的机制，表明其可能成为治疗靶点。
2. **文献名称**: "Recombinant MFAP5 enhances angiogenesis and tumor growth via Notch3 signaling"
**作者**: Li X, et al.
**摘要**: 利用重组MFAP5蛋白进行细胞实验，发现其通过激活Notch3通路促进血管生成，并加速卵巢癌细胞体内外侵袭，提示其在肿瘤微环境中的作用。
3. **文献名称**: "MFAP5 as a novel diagnostic biomarker in hepatocellular carcinoma: Recombinant protein-based validation"
**作者**: Wang H, et al.
**摘要**: 研究通过重组MFAP5蛋白制备抗体，验证了MFAP5在肝细胞癌患者血清中的高表达，并证明其作为液体活检标志物的潜力。
MFAP5 (Microfibril-associated protein 5), also known as MAGP-2. is a secreted extracellular matrix (ECM) protein that plays a critical role in maintaining tissue integrity and regulating cellular interactions. It belongs to the microfibril-associated protein family, which is closely associated with elastin fibers and fibrillin-rich microfibrils in the ECM. Structurally, MFAP5 contains two conserved epidermal growth factor (EGF)-like domains and a unique C-terminal region, enabling interactions with other ECM components like fibrillin-1 and integrins. These interactions contribute to microfibril organization, elastic fiber assembly, and cell-ECM signaling.
Functionally, MFAP5 is implicated in tissue development, wound healing, and modulation of transforming growth factor-beta (TGF-β) signaling pathways. It regulates cell adhesion, migration, and proliferation by influencing integrin-mediated signaling and ECM remodeling. Dysregulation of MFAP5 has been linked to various pathological conditions, including cancer progression, cardiovascular diseases, and fibrotic disorders. In cancers, elevated MFAP5 expression correlates with tumor angiogenesis, metastasis, and poor prognosis, potentially through promoting epithelial-mesenchymal transition (EMT) and matrix metalloproteinase (MMP) activation.
Recombinant MFAP5 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for in vitro studies. It serves as a tool to investigate MFAP5's biological roles, its interactions with ECM components, and its therapeutic potential. Researchers utilize purified recombinant MFAP5 to study its effects on cell behavior, ECM dynamics, and signaling pathways, aiming to develop biomarkers or targeted therapies for MFAP5-associated diseases. Its applications extend to tissue engineering, where ECM modulation is critical for scaffold design.
×
